Wondfo Biotech adjusts convertible bond price after share repurchase

Guangzhou Wondfo Biotech's controlling shareholders, Li Wenmei and Wang Jihua, saw their combined direct holdings increase from 30.62% to 31.50% due to a repurchase and cancellation of restricted shares from the 2024 equity incentive plan. This passive equity change crossed the 1% threshold, triggering the announcement.

The company completed the repurchase and cancellation of 13,340,000 restricted shares on September 17, 2025, from 232 incentive recipients. This action reduced the company's total share capital from 481,424,761 shares to 468,084,761 shares. The total repurchase amount was 167,497,097.28 yuan, funded by the company's own capital.

Consequently, the repurchase and cancellation of these shares led to an adjustment in the conversion price of the "Wondfo Convertible Bond." The conversion price was adjusted from 26.60 yuan per share to 27.00 yuan per share, effective September 18, 2025. This adjustment follows the company's convertible bond prospectus guidelines for changes in share capital.